All In Biotech

Free tool

FAERS Monitor: Tri-Luma

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021112 or its brand name (Tri-Luma, Fluocinolone Acetonide, Hydroquinone, Tretinoin). Reports on generic versions are filed under their own applications.

Reports

548

Serious

47

9% of reports

Hospitalization

15

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • erythema161
  • drug ineffective123
  • skin burning sensation91
  • condition aggravated73
  • skin exfoliation69
  • product use issue54
  • dry skin52
  • pruritus51
  • skin irritation51
  • intentional product use issue50
  • intentional product misuse48
  • skin hyperpigmentation48
  • drug ineffective for unapproved indication43
  • incorrect product storage43
  • product use in unapproved indication39

Reports by year received

View as table
YearReports
20052
20063
20073
20082
20095
20102
20116
20129
20135
20147
201591
201686
2017110
201822
201948
202047
20214
202218
202319
202415
202519
202625

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,611 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin hyperpigmentationSignal48215.6164.49,987
incorrect product storageSignal43126.094.55,194
skin burning sensationSignal9148.840.54,223
skin irritationSignal5142.832.92,041
skin exfoliationSignal6931.425.22,008
drug ineffective for unapproved indicationSignal4330.122.61,183
erythemaSignal16130.126.44,539
intentional product use issueSignal5021.916.8981
intentional product misuseSignal4821.116.1900
dry skinSignal5215.011.5667
product use issueSignal5411.08.6487
condition aggravatedSignal739.27.4534
product use in unapproved indicationSignal396.04.5161
pruritusSignal515.13.9167
drug ineffectiveSignal1233.63.1241

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.